The startup has developed a patented synthetic antimicrobial topical gel that utilizes sustained release of reactive oxygen species (ROS) to effectively combat a wide range of bacterial and fungal pathogens, including those with resistance profiles. This technology provides a solution for infections, nasal decontamination, and medical device coatings, validated by leading research institutes.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for topical infections often struggle with resistant pathogens and can have limitations in their spectrum of activity and safety profile. This can lead to prolonged treatment times, reduced efficacy, and potential side effects for patients.
Solution
Nektr Technologies has developed A3IS, a broad-spectrum antimicrobial platform technology delivered as a topical medicine. A3IS utilizes the sustained release of reactive oxygen species (ROS) to combat a range of bacterial and fungal pathogens, including resistant strains. The lead formulation, Mycosinate, is in late-stage clinical development for the treatment of fungal nail infections (onychomycosis). The A3IS platform's broad antimicrobial activity and safety profile on the skin allows for development of treatments for several other dermatological indications.
Target Audience
The primary target audience includes individuals suffering from topical infections, particularly fungal nail infections, and the clinicians who treat them.
Features
- Broad-spectrum antimicrobial activity against bacterial and fungal pathogens
- Sustained release of reactive oxygen species (ROS)
- Demonstrated efficacy against resistant strains
- Excellent safety profile on skin
- Mycosinate formulation specifically designed for the treatment of onychomycosis